Free Trial

EKF Diagnostics (LON:EKF) Shares Down 7% - Time to Sell?

EKF Diagnostics logo with Medical background

Key Points

  • EKF Diagnostics shares dropped by 7% during trading on Friday, with the stock trading as low as GBX 23.60 ($0.31) before closing at GBX 26 ($0.35).
  • The company reported an earnings per share (EPS) of GBX 0.43 for the last quarter, with analysts forecasting an EPS of 2.30 for the current fiscal year.
  • EKF holds a market capitalization of £116.76 million and has key financial metrics including a price-to-earnings ratio of 19.26 and a return on equity of 7.03%.
  • MarketBeat previews top five stocks to own in November.

EKF Diagnostics Holdings plc (LON:EKF - Get Free Report) shares fell 7% during trading on Friday . The stock traded as low as GBX 23.60 ($0.31) and last traded at GBX 26 ($0.35). 2,281,890 shares changed hands during trading, an increase of 404% from the average session volume of 453,091 shares. The stock had previously closed at GBX 27.95 ($0.37).

EKF Diagnostics Price Performance

The stock has a market capitalization of £116.76 million, a price-to-earnings ratio of 19.26 and a beta of 0.57. The company has a fifty day simple moving average of GBX 29.18 and a 200 day simple moving average of GBX 26.59. The company has a debt-to-equity ratio of 0.34, a quick ratio of 1.77 and a current ratio of 4.60.

EKF Diagnostics (LON:EKF - Get Free Report) last announced its earnings results on Tuesday, September 16th. The company reported GBX 0.43 EPS for the quarter. EKF Diagnostics had a return on equity of 7.03% and a net margin of 9.37%. Equities research analysts forecast that EKF Diagnostics Holdings plc will post 2.2987842 EPS for the current fiscal year.

EKF Diagnostics Company Profile

(Get Free Report)

EKF is an AIM-listed global diagnostics business focussed on: ● Point-of-Care analysers in the key areas of Hematology and Diabetes ● Life Sciences services provide specialist manufacture of enzymes and custom products for use in diagnostic, food and industrial applications. EKF has headquarters in Penarth (near Cardiff) and operates five manufacturing sites across the US and Germany, selling into over 120 countries world-wide.

Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in EKF Diagnostics Right Now?

Before you consider EKF Diagnostics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and EKF Diagnostics wasn't on the list.

While EKF Diagnostics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report
Like this article? Share it with a colleague.